Dube Michael P
SEC CIK 2019493 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | VP, PAO, Interim PFO | 66.9K | — | $184.2K | 9 | 2024-07-01 | 2026-07-01 |
Most active insiders at NTLA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEONARD JOHN M | Pres, CEO, Dir | — | $1.44M |
| 2 | Cohen Fred E | Dir | $1.40M | — |
| 3 | Dulac Edward J III | EVP, CFO | — | $234.2K |
| 4 | BASTA JAMES | EVP, GC | — | $112.4K |
| 5 | Lebwohl David | EVP, Chief Medical Off | — | $109.6K |
| 6 | Dube Michael P | VP, CAO | — | $104.4K |
| 7 | Clark Eliana | EVP, Chief Technical Off | — | $96.0K |
| 8 | Schultes Birgit C | EVP, CSO | — | $78.9K |
| 9 | Bhanji Muna | Dir | — | — |
| 10 | Keresty Georgia | Dir | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 17:02 | 2026-07-01 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | S - Sale | $16.78 | -2,641 | 66.9K | -4% | -$44.3K | |
| 2026-03-03 | 2026-03-01 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | A - Grant | $0.00 | +17.2K | 69.5K | +33% | $0 | |
| 2026-01-07 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | S - Sale | $9.21 | -2,989 | 52.3K | -5% | -$27.5K | |
| 2025-10-03 | 2025-10-01 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | S - Sale | $17.38 | -1,871 | 55.3K | -3% | -$32.5K | |
| 2025-07-03 | 2025-07-02 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | S - Sale | $9.95 | -2,503 | 57.1K | -4% | -$24.9K | |
| 2025-03-04 | 2025-03-01 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | A - Grant | $0.00 | +14.0K | 59.6K | +31% | $0 | |
| 2025-01-07 | 2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | S - Sale | $12.18 | -1,372 | 45.6K | -3% | -$16.7K | |
| 2024-10-04 | 2024-10-02 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, CAO | S - Sale | $19.01 | -2,012 | 47.0K | -4% | -$38.2K | |
| 2024-07-03 | 2024-07-01 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, PAO, Interim PFO | A - Grant | $0.00 | +17.8K | 49.0K | +57% | $0 |
Purchase Sale Sale after option exercise All abbreviations